Essential Thrombocythemia Market Size & Share, by Treatment Type (Interferon, Anagrelide, Hydroxyurea, Aspirin); End-user (Hospitals, Research Organizations, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5044
  • Published Date: Jun 17, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Essential Thrombocythemia Market size is estimated to surpass USD 1.5 Billion by the end of 2035, witnessing at a CAGR of approximately 6% during the forecast period i.e., 2023 – 2035. In the year 2022, the industry size of essential thrombocythemia was nearly USD 865 Million. The market growth is primarily owing to rising cases of essential thrombocythemia (ET). Essential thrombocythemia impacts 1 to 24 individuals among every 1 million people, worldwide. This condition is characterized by the overproduction of platelets in the bone marrow, leading to an increased risk of blood clots. As more people are diagnosed with ET, the demand for effective treatment options and therapies to manage the condition increases, thereby driving the market.

Besides this, special programs by regulatory bodies to facilitate drug development will be an essential factor for essential thrombocythemia market growth. The FDA is putting together a set of four approaches to patient-focused drug development (PFDD) guidelines to aid in the advancement and implementation of organized methods for gathering and utilizing reliable and meaningful patient and opinions of caretakers that can facilitate better drug development and regulatory decision-making. Special programs like these assess the safety and efficacy of new treatments through rigorous clinical trials. Once approved, these drugs can be marketed and made available to patients, driving the ET market by expanding treatment options.

Essential Thrombocythemia Market
Get more information on this report: Request Free Sample PDF

Essential Thrombocythemia Sector: Growth Drivers and Challenges

Growth Drivers

  • Government Initiatives for Rare Diseases –The US National Institutes of Health and the European Commission, launched a joint commission in 2011, International Rare Disease Research Consortium (IRDiRC). Currently, the consortium has 60 organizations all across the world focusing on rare diseases. Moreover, IRDiRC has targeted new plans to reach nearly new therapies for rare diseases by the end of 2027. These initiatives can expedite the review and approval process for orphan drugs, which are drugs developed specifically for rare conditions like ET. Moreover, streamlined regulatory pathways enable faster access to innovative therapies, encouraging investment and development in the ET market.
  • Continuous Development of Treatment– The development of new and more effective treatments for ET leads to improved patient outcomes. Moreover, the availability of a diverse range of treatment options is crucial for addressing the varying need of ET patients. For instance, Bomedemstat Tosylate is in the second phase of development and it is primarily used for the treatment of essential thrombocythemia, and post-essential thrombocythemia myelofibrosis (PET-MF).  
  • Higher Prevalence in Old Adults – In the world, there were around 1 billion old adults in 2019. The population share is expected to rise and reach nearly 1.4 billion and 2.1 billion by 2030 and 2050, respectively. Aging is associated with an increased risk of developing essential thrombocythemia. As individuals age, the accumulation of genetic mutation and exposure to environmental factors over time may contribute to the development of ET. It is most commonly diagnosed in the sixth and seventh decade of an individual’s life.


  • Lack of Opportunities for Clinical Trials – Conducting clinical trials for rare diseases like ET can be challenging due to the relatively small patient population and the need for specialized centers and expertise. Limited clinical trial opportunities can slow down the development of new therapies and hinder advancements in the field
  • Delayed diagnosis and treatment
  • Limited Treatment Options

Essential Thrombocythemia Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 865 Million

Forecast Year Market Size (2035)

~ USD 1.5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Essential Thrombocythemia Segmentation

Treatment Type (Interferon, Anagrelide, Hydroxyurea, Aspirin)

The hydroxyurea segment in the essential thrombocythemia market is anticipated to gain the largest revenue share of about 55% in the year 2035. The rising cases of sickle cell anemia will grow the segment’s growth. Hydroxyurea is considered a disease-modifying therapy for sickle cell anemia. Sickle cell anemia leads to secondary essential thrombocythemia. In sickle cell anemia, chronic inflammation and tissue damage associated with vaso-occulusive crises can stimulate the production of platelets. This can lead to elevated platelet levels in individuals. Every year, approximately 300,000 infants worldwide are born with a serious hemoglobin disorder. Moreover, roughly 250 million people worldwide are currently carriers of the gene responsible for sickle cell disease and associated hemoglobin disorders.

End User (Hospitals, Research Organizations, Specialty Clinics)

The research organization segment is expected to hold 46% share of the global essential thrombocythemia market in the year 2035. Moreover, the segment was responsible for around 65% of the market share in 2022. Researchers are leveraging innovative laboratory methods, genetic profiling, and molecular diagnostics to better understand the genetic and molecular basis of ET. These advancements not only aid in accurate diagnosis but also provide insights into disease progression and potential therapeutic targets. Research organizations are focused on identifying new therapeutic targets for essential thrombocythemia. By unraveling the underlying molecular and genetic abnormalities associated with ET.

Our in-depth analysis of the global market includes the following segments:

     Treatment Type

  • Interferon
  • Anagrelide
  • Hydroxyurea
  • Aspirin

     End User

  • Hospitals
  • Research Organizations
  • Specialty Clinics

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Essential Thrombocythemia Industry- Regional Synopsis

North America Statistics

The essential thrombocythemia market in North America is projected to be the largest with a share of about 35% by the end of 2035. The market growth in the region is mostly driven by the rising count of people living with ET. In the United States, the average yearly prevalence of newly detected cases of ET for every ethnic group and race is roughly 2.2 per 100,000 population. Furthermore, the higher investment influx and development of biotech and pharmaceutical sectors are further driving the industry expansion in North America. Since, ET requires long-term management, often with the use of medication and these medications rely on the availability of high-quality active pharmaceutical ingredients (API), raw materials, and antibiotics. The Department of Health and Humans services invested USD 40 million to drive the growth of biopharmaceuticals in the United States.  

European Market Forecast

The European essential thrombocythemia market is expected to be the second largest, with a share of around 24% by the end of 2035. According to the European Commission, by December 2021, European Union-based enterprises have raised their investments in health research and development by up to 10.3%. Increased investment in health R&D enables researchers to gain a deeper understanding of ET, including its underlying causes, mechanism, and risk factors. This knowledge contributes to the development of more personalized therapies for ET.

Research Nester
Essential Thrombocythemia Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Essential Thrombocythemia Landscape

    • Active Biotech AB
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Incyte
    •  Bayer AG
    • USV Private Limited.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited

In the News

  • Active Biotech AB announced the approval for tasquinimod Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of myelofibrosis. It creates an important regulatory channel and gives us the opportunity to rapidly progress tasquinimod development in this patient population.
  • Incyte has announced to receive data from two Limber trials assessing single-agent therapy and combination treatments in patients with myelofibrosis (MF) using ruxolitinib with parsaclisib.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5044
  • Published Date: Jun 17, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing cases of essential thrombocythemia, and rising investment in research development of new drugs are the major factors driving the market growth.

The market size of essential thrombocythemia is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Incyte, Bayer AG, Merck & Co., Inc.., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited., and Active Biotech AB.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment type, end user, and by region.

The hydroxyurea segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Lack of treatment, underdiagnosis and misdiagnosis, and slow clinical trials are estimated to be the growth-hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Essential Thrombocythemia Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying